Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 12/20 | 0.62 |
| ▸ | CHRNA3 | P32297 | 11/20 | 0.62 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14941778 | 1.00 | CHRNB2 (0.62) | CHRNB2CHRNA3CHRNA2CHRNB4CHRNA4 | |
| SCHEMBL6584907 | 0.96 | CHRNA3 (0.58) | CHRNB2CHRNA3CHRNA2CHRNB4CHRNA4 | |
| SCHEMBL14941891 | 0.95 | CHRNB2 (0.68) | CHRNB2CHRNA3CHRNA2CHRNB4CHRNA4 | |
| SCHEMBL14941878 | 0.95 | CHRNB2 (0.68) | CHRNB2CHRNA3CHRNA2CHRNB4CHRNA4 | |
| SCHEMBL12807443 | 0.93 | CHRNA3 (0.60) | CHRNB2CHRNA3CHRNA2CHRNB4CHRNA4 | |
| SCHEMBL2494032 | 0.92 | CHRNA3 (0.64) | CHRNB2CHRNA3CHRNA2CHRNB4CHRNA4 | |
| SCHEMBL6586979 | 0.91 | CHRNA3 (0.63) | CHRNB2CHRNA3CHRNA2CHRNB4CHRNA4 | |
| SCHEMBL6587133 | 0.91 | CHRNA3 (0.63) | CHRNB2CHRNA3CHRNA2CHRNB4CHRNA4 | |
| SCHEMBL2497766 | 0.91 | CHRNB2 (0.63) | CHRNB2CHRNA3CHRNA2CHRNB4CHRNA4 | |
| SCHEMBL12807581 | 0.90 | CHRNB2 (0.49) | CHRNB2CHRNA3CHRNA2CHRNB4CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776030-B1 | 2,5-DISUBSTITUTED-PYRIDYL NICOTINIC LIGANDS, AND METHODS OF USE THEREOF | UNIV GEORGETOWN (US) | 2020-05-13 | — | — | EP | disclosed |
| US-9993465-B2 | 2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170035743-A1 | 2,5-Disubstituted-Pyridyl Nicotinic Ligands, and Methods of Use Thereof | DUKE UNIVERSITY | 2017-02-09 | — | — | US | disclosed |
| US-9303017-B2 | 2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2016-04-05 | — | — | US | disclosed |
| US-20140378428-A1 | 2,5-Disubstituted-Pyridyl Nicotinic Ligands, and Methods of Use Thereof | GEORGETOWN UNIVERSITY (US) | 2014-12-25 | — | — | US | disclosed |
| EP-2776030-A1 | 2,5-DISUBSTITUTED-PYRIDYL NICOTINIC LIGANDS, AND METHODS OF USE THEREOF | Georgetown University (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013071097-A1 | 2,5-DISUBSTITUTED-PYRIDYL NICOTINIC LIGANDS, AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2013-05-16 | — | — | WO | disclosed |
| EP-0934308-B1 | 3-PYRIDYLOXYMETHYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LAB (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6437138-B1 | 5-BROMO-6-CHLORO-3-(2-(S)-AZETIDINYL OR PYRROLIDINYL-METHOXY) PYRIDINE INTERMEDIATES FOR THE 5-SUBSTITUTED COMPOUNDS WHICH ARE POTENT LIGANDS AT NEURONAL NICOTINIC CHOLINERGIC CHANNEL RECEPTORS, NEUROTRANSMITTER CONTROLLING AGENTS | ABBOTT LABORATORIES | 2002-08-20 | — | — | US | disclosed |
| US-6127386-A | STIMULANTS, NEUROTRANSMITTERS, CHOLINERGIC AGENTS | ABBOTT LABORATORIES (US) | 2000-10-03 | — | — | US | disclosed |
| US-5629325-A | TREATMENT OF NERVOUS SYSTEM DISORDERS; NEURONAL NICOTINIC CHOLINERGIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378428-A1 | 2,5-Disubstituted-Pyridyl Nicotinic Ligands, and Methods of Use Thereof | CHRNA4, CHRNA5, OPRL1 | CHRNB2 14/4885CHRNA3 35/4885CHRNA2 4/4885 |
| US-20170035743-A1 | 2,5-Disubstituted-Pyridyl Nicotinic Ligands, and Methods of Use Thereof | CHRNA4, CHRNA5, OPRL1 | CHRNB2 14/4885CHRNA3 35/4885CHRNA2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.